![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage firm that goals to set up gene remedy as a brand new commonplace of take care of extremely prevalent ocular ailments, at this time introduced that Peter Soparkar, chief working officer of Adverum Biotechnologies, will current at the Jefferies Cell and Genetic Medicine Summit on September 29, 2022, at 9:30 a.m. ET.
The on-demand webcast company presentation could also be accessed below Events and Presentations in the Investors part of Adverum’s web site. A replay of the webcast might be out there on the web site for 90 days following the presentation.
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage firm that goals to set up gene remedy as a brand new commonplace of take care of extremely prevalent ocular ailments with the aspiration of creating purposeful cures to restore imaginative and prescient and stop blindness. Leveraging the analysis capabilities of its proprietary, intravitreal (IVT) platform, Adverum is creating sturdy, single-administration therapies, designed to be delivered in physicians’ places of work, to get rid of the want for frequent ocular injections to deal with these ailments. Adverum is evaluating its novel gene remedy candidate, ixoberogene soroparvovec (Ixo-vec, previously referred to as ADVM-022), as a one-time, IVT injection for sufferers with neovascular or moist age-related macular degeneration. By overcoming the challenges related to present remedy paradigms for these debilitating ocular ailments, Adverum aspires to remodel the commonplace of care, protect imaginative and prescient, and create a profound societal influence round the globe. For extra data, please go to www.adverum.com.
Corporate & Investor Inquiries
Anand Reddi
Vice President, Head of Corporate Strategy, External Affairs and Engagement
Adverum Biotechnologies, Inc.
T: 650-649-1358
E: [email protected]
Media
Megan Talon
Associate Director, Corporate Communications
Adverum Biotechnologies, Inc.
T: 650-649-1006
E: [email protected]
